Form 10-K Arcturus Therapeutics For: Dec 31
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/29/2026
- S&P 500 ends lower; chips tumble and Moderna rallies
- SpaceX weighs Starlink mobile service to US consumers, FT reports
- U.S. chip stocks retreat after Apple price hikes stoke fears over AI trade
- Morgan Stanley flags Fed hike risk if unemployment drops below 4%
- UBS trims AI portfolio exposure to semis and hardware after recent rally
Arcturus Therapeutics (ARCT) PT Lowered to $65 at Leerink Partners
March 7, 2025 5:47 AM ESTLeerink Partners analyst Lili Nsongo lowered the price target on Arcturus Therapeutics (NASDAQ: ARCT) to $65.00 (from $70.00) while maintaining a Outperform rating.
The analyst comments "Bottom Line: Today after close, ARCT reported FY24 earnings and provided a pipeline update. In the partnered vaccine... More
